Dataset Information

Gene expression profiling of Human Hepatocellular Carcinoma tissues

ABSTRACT: Hepatocellular carcinoma (HCC) is the fifth most common malignancy of cancer-related deaths worldwide, and prognosis of patients with HCC still remain unsatisfactory. Therefore, more reliable biomarkers for predicting the disease and understanding the mechanisms underlying cancer development need to be found out urgently. In this study, we explored the clinical significance and role of ALDOB, G6PD in HCC pathogenesis. Here we show that low ALDOB expression with high G6PD expression lead to patients' poor survival and prognosis by remodeling metabolic pathway and increasing tumor proliferation and metastasis. Stat5a regulates ALDOB expression positively but negatively to G6PD expression in mRNA level, simultaneously, ALDOB inhibits G6PD enzymatic activity by protein-protein interaction and we have found one of their interaction sites in ALDOB. These data suggest that ALDOB and G6PD could be potential biomarkers for HCC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE74656 | GEO | 2015/11/04

SECONDARY ACCESSION(S): PRJNA301075

REPOSITORIES: GEO

ACCESS DATA

Similar Datasets

Project description:Gene-expression profiles of hepatitis C-related, early-stage liver cirrhosis Background & Aims: Liver cirrhosis affects 1%M-bM-^HM-^R2% of population and is the major risk factor of hepatocellular carcinoma (HCC). Hepatitis C cirrhosis-related HCC is the most rapidly increasing cause of cancer death in the US. Non-invasive methods have been developed to identify patients with asymptomatic, early-stage cirrhosis, increasing the burden of HCC surveillance, but biomarkers are needed to identify patients with cirrhosis who are most in need of surveillance. We investigated whether a liver-derived 186-gene signature previously associated with outcomes of patients with HCC is prognostic for patients newly diagnosed with cirrhosis but without HCC. Methods: We performed gene expression profile analysis of formalin-fixed needle biopsies from the livers of 216 patients with hepatitis C-related early-stage (Child-Pugh class A) cirrhosis who were prospectively followed for a median of 10 years at an Italian center. We evaluated whether the 186-gene signature was associated with death, progression of cirrhosis, and development of HCC. Results: Fifty-five (25%), 101 (47%), and 60 (28%) patients were classified as having poor-, intermediate-, and good-prognosis signatures, respectively. In multivariable Cox regression modeling, the poor-prognosis signature was significantly associated with death (P=.004), progression to advanced cirrhosis (P<.001), and development of HCC (P=.009). The 10-year rates of survival were 63%, 74%, and 85% and the annual incidences of HCC were 5.8%, 2.2%, and 1.5% for patients with poor-, intermediate-, and good-prognosis signatures, respectively. Conclusions: A 186-gene signature used to predict outcomes of patients with HCC is also associated with outcomes of patients with hepatitis C-related early-stage cirrhosis. This signature might be used to identify patients with cirrhosis in most need of surveillance and strategies to prevent their development of HCC. 216 liver biopsy specimens

Dataset Information

Gene expression profiling of Human Hepatocellular Carcinoma tissues

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure